GlaxoSmithKline plc (NYSE:GSK) Receives Consensus Rating of “Hold” from Analysts

GlaxoSmithKline plc (NYSE:GSK) has received an average recommendation of “Hold” from the seventeen ratings firms that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and three have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $41.50.

Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, August 13th. Societe Generale raised shares of GlaxoSmithKline from a “sell” rating to a “buy” rating in a research note on Tuesday, September 3rd. Cowen reaffirmed a “hold” rating and set a $45.00 target price on shares of GlaxoSmithKline in a research note on Monday, June 10th. ValuEngine cut shares of GlaxoSmithKline from a “hold” rating to a “sell” rating in a research note on Tuesday, September 10th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of GlaxoSmithKline in a research note on Thursday, August 29th.

In other GlaxoSmithKline news, Director Plc Glaxosmithkline bought 333,333 shares of the stock in a transaction on Monday, July 1st. The shares were bought at an average price of $15.00 per share, with a total value of $4,999,995.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 10.00% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Berman Capital Advisors LLC lifted its position in GlaxoSmithKline by 58.1% in the second quarter. Berman Capital Advisors LLC now owns 656 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares during the last quarter. Sigma Planning Corp lifted its position in GlaxoSmithKline by 0.8% in the second quarter. Sigma Planning Corp now owns 32,090 shares of the pharmaceutical company’s stock valued at $1,284,000 after buying an additional 250 shares during the last quarter. Trillium Asset Management LLC lifted its position in GlaxoSmithKline by 2.2% in the second quarter. Trillium Asset Management LLC now owns 11,519 shares of the pharmaceutical company’s stock valued at $461,000 after buying an additional 252 shares during the last quarter. CIBC Private Wealth Group LLC lifted its position in GlaxoSmithKline by 1.8% in the second quarter. CIBC Private Wealth Group LLC now owns 14,824 shares of the pharmaceutical company’s stock valued at $593,000 after buying an additional 261 shares during the last quarter. Finally, Essex Financial Services Inc. lifted its position in GlaxoSmithKline by 4.0% in the second quarter. Essex Financial Services Inc. now owns 6,990 shares of the pharmaceutical company’s stock valued at $280,000 after buying an additional 269 shares during the last quarter. 11.12% of the stock is currently owned by hedge funds and other institutional investors.

NYSE GSK traded up $0.31 on Friday, hitting $41.63. The company had a trading volume of 2,908,350 shares, compared to its average volume of 1,999,852. The company has a market capitalization of $103.06 billion, a PE ratio of 13.17, a PEG ratio of 2.00 and a beta of 0.70. The company’s fifty day moving average price is $41.03 and its 200-day moving average price is $40.60. The company has a debt-to-equity ratio of 7.86, a current ratio of 0.71 and a quick ratio of 0.48. GlaxoSmithKline has a 12-month low of $36.41 and a 12-month high of $42.49.

GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.64 by $0.14. The company had revenue of $10.04 billion during the quarter, compared to analyst estimates of $9.55 billion. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 175.45%. On average, sell-side analysts anticipate that GlaxoSmithKline will post 2.95 EPS for the current year.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

See Also: Strike Price

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.